Header Logo

MALCOLM BRENNER

TitleDistinguished Service Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address6621 FANNIN
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleDistinguished Service Professor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleDistinguished Service Professor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Hematology & Oncology

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular & Human Genetics
    DivisionMolecular & Human Genetics


    Collapse Research 
    Collapse research activities and funding
    P50CA126752     (HESLOP, HELEN E)Apr 1, 2007 - Aug 31, 2022
    NIH
    SPORE in Lymphoma
    Role: Co-Principal Investigator
    U54HL081007     (BRENNER, MALCOLM K)Sep 30, 2005 - Aug 31, 2011
    NIH
    Improving the safety and efficacy of cell therapies
    Role: Principal Investigator
    R21CA108143     (BRENNER, MALCOLM K)Apr 1, 2004 - Mar 31, 2006
    NIH
    Combined CTL and CD45 antibody for nasopharyngeal carci*
    Role: Principal Investigator
    R13DK062214     (BRENNER, MALCOLM K)Jun 1, 2002 - Jun 30, 2003
    NIH
    5th Annual Meeting, American Society of Gene Therapy
    Role: Principal Investigator
    U42RR016578     (BRENNER, MALCOLM K)Sep 30, 2001 - Aug 31, 2007
    NIH
    ADENOVIRAL VECTOR PRODUCTION AT BAYLOR
    Role: Principal Investigator
    R21CA093069     (BRENNER, MALCOLM K)May 1, 2001 - Apr 30, 2004
    NIH
    Haploidentical Allogeneic Transplantation
    Role: Principal Investigator
    R21CA082101     (BRENNER, MALCOLM K)Aug 6, 1999 - Jun 30, 2001
    NIH
    CD45 ANTIBODY EFFECT ON NORMAL AND MALIGNANT HEMOPOIESIS
    Role: Principal Investigator
    R01CA078792     (BRENNER, MALCOLM K)Sep 30, 1998 - Jul 31, 2004
    NIH
    THERAPEUTIC EFFECTS OF CD40L IN ACUTE LYMPHOBLASTIC LEUK
    Role: Principal Investigator
    R01CA075014     (BRENNER, MALCOLM K)Sep 1, 1997 - Jun 30, 2002
    NIH
    ACTIVITY OF LYMPHOTACTIN IN CHILDHOOD MALIGNANCY
    Role: Principal Investigator
    U01CA058211     (BRENNER, MALCOLM K)Sep 30, 1992 - Sep 29, 1996
    NIH
    TREATMENT OF NEUROBLASTOMA WITH IL2 TRANSDUCED TUMOR
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Martinez C, Aguayo-Hiraldo P, Chimowitz N, Forbes L, Rider NL, Nicholas S, Seeborg F, Chinen J, Chinn IK, Davis C, Rosenblatt HM, Noroski LM, Omer B, John TD, Yassine K, Naik S, Craddock J, Bhar S, Allen C, Ahmed N, Sasa G, Steffin D, Doherty EE, George A, Salem B, Friend BD, Hegde M, Brenner MK, Heslop HE, Leen A, Wu M, Hanson C, Krance RA, Pe?a AM, Martinez C, Aguayo-Hiraldo P, Chaimowitz N, Forbes L, Rider N, Nicholas S, Seeborg F, Chinen J, Chinn I, Davis C, Roseblatt H, Noroski L, Omer B, John T, Yassine K, Naik S, Craddock J, Bhar S, Allen C, Ahmed N, Sasa G, Steffin D, Doherty E, George A, Salem B, Friend B, Hegde M, Brenner MK, Heslop HE, Leen A, Pe?a A, Wu M, Hanson IC, Krance RA. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830. PMID: 36453638; PMCID: PMC10165184.
      Citations:    
    2. Sharma S, Woods M, Mehta NU, Sauer T, Parikh KS, Schmuck-Henneresse M, Zhang H, Mehta B, Brenner MK, Heslop HE, Rooney CM. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 Apr; 11(4). PMID: 37072346; PMCID: PMC10124261.
      Citations:    Fields:    Translation:HumansAnimalsCells
    3. Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, Xu Y, Biegert GGW, Morita D, Wang T, Grilley BJ, Heslop H, Brenner MK, Suzuki M. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790. PMID: 36989357; PMCID: PMC10058234.
      Citations:    Fields:    Translation:AnimalsCells
    4. Mo F, Watanabe N, Omdahl KI, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, Brenner MK, Tkachev V, Mamonkin M. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208. PMID: 36044667; PMCID: PMC10023730.
      Citations:    
    5. Lulla PD, Brenner M. Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27. PMID: 36693154; PMCID: PMC9881841.
      Citations:    Fields:    Translation:HumansCells
    6. McKenna MK, Ozcan A, Brenner D, Watanabe N, Legendre M, Thomas DG, Ashwood C, Cummings RD, Bonifant C, Markovitz DM, Brenner MK. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma. J Immunother Cancer. 2023 01; 11(1). PMID: 36653070; PMCID: PMC9853244.
      Citations:    Fields:    Translation:HumansAnimalsCells
    7. Cornetta K, Yao J, House K, Duffy L, Adusumilli PS, Beyer R, Booth C, Brenner M, Curran K, Grilley B, Heslop H, Hinrichs CS, Kaplan RN, Kiem HP, Kochenderfer J, Kohn DB, Mailankody S, Norberg SM, O'Cearbhaill RE, Pappas J, Park J, Ramos C, Ribas A, Rivi?re I, Rosenberg SA, Sauter C, Shah NN, Slovin SF, Thrasher A, Williams DA, Lin TY. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809. PMID: 36518078; PMCID: PMC10014217.
      Citations:    Fields:    Translation:HumansCells
    8. Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients. Haematologica. 2022 Nov 10. PMID: 36373249.
      Citations:    
    9. Watanabe N, Mo F, Zheng R, Ma R, Bray VC, van Leeuwen DG, Sritabal-Ramirez J, Hu H, Wang S, Mehta B, Srinivasan M, Scherer LD, Zhang H, Thakkar SG, Hill LC, Heslop HE, Cheng C, Brenner MK, Mamonkin M. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34. PMID: 36086817; PMCID: PMC9840107.
      Citations:    
    10. Raglow Z, McKenna MK, Bonifant CL, Wang W, Pasca di Magliano M, Stadlmann J, Penninger JM, Cummings RD, Brenner MK, Markovitz DM. Targeting glycans for CAR therapy: The advent of sweet CARs. Mol Ther. 2022 09 07; 30(9):2881-2890. PMID: 35821636; PMCID: PMC9481985.
      Citations:    Fields:    
    11. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    12. Atilla PA, McKenna MK, Watanabe N, Mamonkin M, Brenner MK, Atilla E. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022 03; 24(3):282-290. PMID: 34955406; PMCID: PMC8950815.
      Citations:    Fields:    Translation:AnimalsCellsCTClinical Trials
    13. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 Dec 01; 29(12):3529-3533. PMID: 34706248; PMCID: PMC8636171.
      Citations: 1     Fields:    
    14. Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. PMID: 34377737; PMCID: PMC8322039.
      Citations: 2     
    15. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2021 07 01; 131(13). PMID: 34196303; PMCID: PMC8245163.
      Citations: 2     Fields:    
    16. Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597. PMID: 33270816; PMCID: PMC8120140.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    17. Ferrari F, Salviato E, Brenner MK, Gottschalk S, Hoyos V, Arnone CM, Polito VA, Mastronuzzi A, Carai A, Diomedi FC, Antonucci L, Petrilli LL, Vinci M, Scarsella M, De Stefanis C, Weber G, Quintarelli C, De Angelis B, Locatelli F, Caruana I, Del Bufalo F. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5). PMID: 33963009; PMCID: PMC8108682.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    18. Mamonkin M, Brenner MK. Reversal of exhaustion in engineered T cells. Science. 2021 04 02; 372(6537):34-35. PMID: 33795449.
      Citations: 2     Fields:    Translation:Cells
    19. Rosewell Shaw A, Porter CE, Yip T, Mah WC, McKenna MK, Dysthe M, Jung Y, Parihar R, Brenner MK, Suzuki M. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368. PMID: 33742099; PMCID: PMC7979740.
      Citations: 7     Translation:HumansCells
    20. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820. PMID: 33571680; PMCID: PMC8116608.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    21. Mo F, Mamonkin M, Brenner MK, Heslop HE. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272. PMID: 33536140; PMCID: PMC7914205.
      Citations: 5     Fields:    Translation:HumansCells
    22. Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum G. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425. PMID: 33507803; PMCID: PMC8274795.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    23. Bajwa G, Cardenas M, Brenner MK, Arber C, Lanz I. Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells. J Immunother Cancer. 2020 11; 8(2). PMID: 33148692; PMCID: PMC7640589.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    24. Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, Simons BW, McLean Stevens A, Redell MS, Heslop HE, Mamonkin M, Brenner MK, Atilla E. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2). PMID: 32938629; PMCID: PMC7497527.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    25. Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554). PMID: 32727914.
      Citations: 11     Fields:    Translation:Humans
    26. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804. PMID: 32701411; PMCID: PMC7655020.
      Citations: 57     Fields:    Translation:HumansCTClinical Trials
    27. Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549. PMID: 32669548; PMCID: PMC7363864.
      Citations: 33     Fields:    Translation:HumansCells
    28. Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63. PMID: 32661440; PMCID: PMC7854790.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    29. Rath JA, Bajwa G, Carreres B, Hoyer E, Gruber I, Yu YR, Nouraee N, Sadeghi F, Wu M, Wang T, Hebeisen M, Rufer N, Varadarajan N, Ho PC, Brenner MK, Gfeller D, Arber C, Mart?nez-Paniagua MA. Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells. Sci Adv. 2020 07; 6(27):eaaz7809. PMID: 32923584; PMCID: PMC7455496.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    30. Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK, Suzuki M. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262. PMID: 32145203; PMCID: PMC7210703.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    31. Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350. PMID: 31558475; PMCID: PMC7062259.
      Citations: 13     Fields:    Translation:HumansCells
    32. Naik S, Martinez CA, Omer B, Sasa G, Yassine K, Allen CE, Kamdar K, Orth R, Wu M, Leung K, Gottschalk S, Brenner MK, Heslop HE, Krance RA. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695. PMID: 31511228; PMCID: PMC6759733.
      Citations: 2     Fields:    Translation:Humans
    33. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2019 Jul 02; 129(8):3464. PMID: 31264975; PMCID: PMC6668664.
      Citations: 10     Fields:    
    34. Lulla PD, Mamonkin M, Brenner MK. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207. PMID: 31135527; PMCID: PMC6602906.
      Citations: 2     Fields:    Translation:Humans
    35. Brenner MK. Adoptive Cell Therapy: ACT-Up or ACT-Out? Mol Ther. 2019 04 10; 27(4):693-694. PMID: 30850208; PMCID: PMC6453505.
      Citations: 3     Fields:    Translation:Humans
    36. Scherer LD, Brenner MK, Mamonkin M. Chimeric Antigen Receptors for T-Cell Malignancies. Front Oncol. 2019; 9:126. PMID: 30891427; PMCID: PMC6411696.
      Citations: 17     
    37. Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Ramos CA, Brenner MK, Mamonkin M, Gomes-Silva D, Cabral JMS. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280. PMID: 30391141; PMCID: PMC6318703.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    38. McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361. PMID: 30262660; PMCID: PMC6265652.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    39. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737. PMID: 30309819; PMCID: PMC6277484.
      Citations: 77     Fields:    Translation:HumansCells
    40. Enblad G, Karlsson H, Wenthe J, Amini RM, Wikstrom KI, Essand M, Savoldo B, Dotti G, Brenner MK, Hagberg H, Loskog A, Gammelg?rd G, L?vgren T, Hallb??k H, H?glund M. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194. PMID: 30097433.
      Citations: 70     Fields:    Translation:HumansCellsCTClinical Trials
    41. Sukumaran S, Watanabe N, Bajgain P, Raja K, Mohammed S, Fisher WE, Brenner MK, Leen AM, Vera JF. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987. PMID: 29880586; PMCID: PMC6428579.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    42. Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34. PMID: 29747685; PMCID: PMC5944113.
      Citations: 39     Fields:    Translation:Humans
    43. Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, Carrum G, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, Brenner MK, Krance RA, Martinez CA. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650. PMID: 29630926.
      Citations: 8     Fields:    Translation:Humans
    44. Brenner MK. Onward and upward for immuno-oncology. Chin Clin Oncol. 2018 04; 7(2):18. PMID: 29764163.
      Citations:    Fields:    Translation:Humans
    45. Yanir AD, Martinez CA, Sasa G, Leung K, Gottschalk S, Omer B, Ahmed N, Hegde M, Eunji J, Liu H, Heslop HE, Brenner MK, Krance RA, Naik S. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431. PMID: 29550628.
      Citations: 8     Fields:    Translation:Humans
    46. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139. PMID: 29315015; PMCID: PMC5891126.
      Citations: 75     Fields:    Translation:HumansCells
    47. Heslop HE, Brenner MK. Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2. PMID: 29273500; PMCID: PMC5763151.
      Citations: 1     Fields:    Translation:HumansCells
    48. Ngwube A, Hanson IC, Orange J, Rider NL, Seeborg F, Shearer W, Noroski L, Nicholas S, Forbes L, Leung K, Sasa G, Naik S, Hegde M, Omer B, Ahmed N, Allen C, Gottschalk S, Wu MF, Liu H, Brenner M, Heslop H, Krance R, Martinez C. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541. PMID: 29196075.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    49. Nishimura CD, Brenner DA, Mukherjee M, Hirsch RA, Ott L, Wu MF, Liu H, Dakhova O, Orange JS, Brenner MK, Lin CY, Arber C. c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood. 2017 12 21; 130(25):2739-2749. PMID: 29079582; PMCID: PMC5746163.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    50. Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, Krenciute G, Orange JS, Brenner MK. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58. PMID: 29079655; PMCID: PMC5963729.
      Citations: 35     Fields:    Translation:AnimalsCells
    51. Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, Rooney CM, Orange JS, Brenner MK, Mamonkin M, Gomes-Silva D, Cabral JMS. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26. PMID: 28978471; PMCID: PMC5645034.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    52. Brenner MK. Next Steps in the CAR Journey of a Thousand Miles. Mol Ther. 2017 10 04; 25(10):2226-2227. PMID: 28939089; PMCID: PMC5628925.
      Citations: 3     Fields:    Translation:HumansCells
    53. Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451. PMID: 28974431; PMCID: PMC5675597.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    54. Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247. PMID: 28830878; PMCID: PMC5669830.
      Citations: 93     Fields:    Translation:HumansAnimalsCells
    55. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471. PMID: 28805662; PMCID: PMC5669573.
      Citations: 140     Fields:    Translation:HumansCellsCTClinical Trials
    56. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452; PMCID: PMC5662844.
      Citations: 135     Fields:    Translation:HumansCellsCTClinical Trials
    57. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101. PMID: 28426845; PMCID: PMC5747970.
      Citations: 269     Fields:    Translation:HumansCellsCTClinical Trials
    58. Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213. PMID: 28676343; PMCID: PMC5589064.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    59. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224. PMID: 28602436; PMCID: PMC5589058.
      Citations: 168     Fields:    Translation:HumansCells
    60. Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296. PMID: 28539325; PMCID: PMC5520470.
      Citations: 131     Fields:    Translation:HumansAnimalsCells
    61. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051. PMID: 28235763; PMCID: PMC5392365.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    62. Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258. PMID: 28129119; PMCID: PMC5363304.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    63. Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017 Jan; 27(1):59-73. PMID: 28008927; PMCID: PMC5223233.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    64. Frederickson RM, Brenner MK. Introducing Molecular Therapy-Oncolytics. Mol Ther. 2014 Jun; 22(6):1065-1066. PMID: 28142017; PMCID: PMC4048904.
      Citations:    Fields:    
    65. Frederickson RM, Brenner MK. Introducing eJP. Mol Ther. 2010 Jun; 18(6):1057. PMID: 28178493; PMCID: PMC2889734.
      Citations:    Fields:    
    66. Brenner M. Interesting Times: Molecular Therapy and the Evolving Media of Scientific Publishing. Mol Ther. 2010 Jan; 18(1):1-2. PMID: 28178548; PMCID: PMC2839216.
      Citations:    Fields:    
    67. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016; 5(12):e1253656. PMID: 28180032; PMCID: PMC5214260.
      Citations: 78     Fields:    
    68. Zhou X, Brenner MK. Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016 Nov; 44(11):1013-1019. PMID: 27473568; PMCID: PMC5083205.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    69. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52. PMID: 27427982; PMCID: PMC4966331.
      Citations: 249     Fields:    Translation:HumansAnimalsCells
    70. Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96. PMID: 27270177; PMCID: PMC4922690.
      Citations: 131     Fields:    Translation:HumansCellsCTClinical Trials
    71. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016 Jun; 24(6):1135-1149. PMID: 27019998; PMCID: PMC4923328.
      Citations: 136     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    72. Yagyu S, Hoyos V, Brenner MK, Del Bufalo F. Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther Methods Clin Dev. 2016; 3:16003. PMID: 27626039; PMCID: PMC5008202.
      Citations: 8     
    73. Manzo T, Hoyos V, Yagyu S, Jacot J, Benavides O, Rosen D, Brenner MK, Del Bufalo F, Caruana I. 3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85. PMID: 26826297.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    74. Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31. PMID: 26708005; PMCID: PMC4886936.
      Citations: 20     Fields:    Translation:HumansCells
    75. Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45. PMID: 26639404; PMCID: PMC4886929.
      Citations: 7     Fields:    Translation:HumansCells
    76. Ando M, Nishimura T, Yamazaki S, Yamaguchi T, Kawana-Tachikawa A, Hayama T, Nakauchi Y, Ando J, Ota Y, Takahashi S, Nishimura K, Ohtaka M, Nakanishi M, Miles JJ, Burrows SR, Nakauchi H, Brenner MK. A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports. 2015 Oct 13; 5(4):597-608. PMID: 26321144; PMCID: PMC4624898.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    77. Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83. PMID: 26332003; PMCID: PMC4732525.
      Citations: 56     Fields:    Translation:HumansCells
    78. Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506. PMID: 26084970; PMCID: PMC4817892.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    79. Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92. PMID: 26056165; PMCID: PMC4543231.
      Citations: 108     Fields:    Translation:HumansAnimals
    80. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85. PMID: 26022733; PMCID: PMC4817893.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    81. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13. PMID: 25977584; PMCID: PMC4481597.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    82. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16. PMID: 25940712; PMCID: PMC4473118.
      Citations: 125     Fields:    Translation:HumansAnimalsCells
    83. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96. PMID: 25800760; PMCID: PMC4429176.
      Citations: 373     Fields:    Translation:HumansCellsCTClinical Trials
    84. Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72. PMID: 25765555.
      Citations: 10     Fields:    Translation:Humans
    85. Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5. PMID: 25734008; PMCID: PMC4346112.
      Citations: 17     Fields:    
    86. Zhou X, Di Stasi A, Brenner MK. iCaspase 9 Suicide Gene System. Methods Mol Biol. 2015; 1317:87-105. PMID: 26072403; PMCID: PMC4903016.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    87. Frederickson RM, Brenner MK. A question of reproducibility. Mol Ther. 2014 Dec; 22(12):2015. PMID: 25434411; PMCID: PMC4429702.
      Citations:    Fields:    Translation:Humans
    88. Brenner MK. Where is the good in goodbye? Mol Ther. 2014 Nov; 22(11):1873-4. PMID: 25365980; PMCID: PMC4429740.
      Citations:    Fields:    
    89. Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK, Bouchier-Hayes L. Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482. PMID: 25323693; PMCID: PMC4245333.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    90. Brenner MK. Gene-modified cells for stem cell transplantation and cancer therapy. Hum Gene Ther. 2014 Jul; 25(7):563-9. PMID: 25029600; PMCID: PMC4098817.
      Citations: 1     Fields:    Translation:HumansAnimals
    91. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83. PMID: 24964991; PMCID: PMC4181611.
      Citations: 158     Fields:    Translation:HumansCellsCTClinical Trials
    92. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905. PMID: 24753538; PMCID: PMC4064331.
      Citations: 86     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    93. Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, Leen AM, Heslop HE. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138. PMID: 24651135; PMCID: PMC4048900.
      Citations: 15     Fields:    Translation:HumansCells
    94. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220. PMID: 24732709; PMCID: PMC4048899.
      Citations: 82     Fields:    Translation:HumansAnimalsCells
    95. Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29. PMID: 24517423; PMCID: PMC3927231.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    96. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25. PMID: 24573552; PMCID: PMC3989436.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    97. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan; 257(1):107-26. PMID: 24329793; PMCID: PMC3874724.
      Citations: 230     Fields:    Translation:HumansAnimalsCells
    98. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808. PMID: 24344220; PMCID: PMC3940538.
      Citations: 208     Fields:    Translation:HumansCellsCTClinical Trials
    99. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633. PMID: 24213558; PMCID: PMC3945803.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    100. Anurathapan U, Leen AM, Brenner MK, Vera JF. Engineered T cells for cancer treatment. Cytotherapy. 2014 Jun; 16(6):713-33. PMID: 24239105; PMCID: PMC4013208.
      Citations: 7     Fields:    Translation:HumansCells
    101. Brenner MK. CAR T cells for acute myeloid leukemia: the LeY of the land. Mol Ther. 2013 Nov; 21(11):1983-4. PMID: 24201214; PMCID: PMC3831052.
      Citations: 5     Fields:    Translation:HumansCells
    102. Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B, Dotti G, Perna SK. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9. PMID: 24097874; PMCID: PMC4113428.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    103. Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456. PMID: 24079872; PMCID: PMC3916772.
      Citations: 15     Fields:    Translation:HumansAnimals
    104. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73. PMID: 24030379; PMCID: PMC3811171.
      Citations: 231     Fields:    Translation:HumansCellsCTClinical Trials
    105. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21. PMID: 23783429; PMCID: PMC3831033.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    106. Arber C, Brenner MK, Reddy P. Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44. PMID: 24216170; PMCID: PMC3971726.
      Citations: 8     Fields:    Translation:HumansAnimals
    107. Frederickson RM, Brenner MK. Introducing molecular therapy--methods & clinical development. Mol Ther. 2013 Jun; 21(6):1105. PMID: 23728249; PMCID: PMC3677310.
      Citations:    Fields:    Translation:Humans
    108. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23. PMID: 23610374; PMCID: PMC3695359.
      Citations: 209     Fields:    Translation:HumansCells
    109. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76. PMID: 23211628; PMCID: PMC3521877.
      Citations: 34     Fields:    Translation:HumansCells
    110. Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18. PMID: 23152545; PMCID: PMC3709638.
      Citations: 41     Fields:    Translation:HumansCells
    111. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17. PMID: 23149818; PMCID: PMC3693218.
      Citations: 40     Fields:    Translation:HumansCells
    112. Frederickson RM, Brenner MK. Introducing a new ASGCT forum for publication of methodology and clinical development in gene, cell, and oligonucleotide therapies. Mol Ther. 2012 Nov; 20(11):2005-6. PMID: 23131848; PMCID: PMC3498806.
      Citations: 1     Fields:    Translation:Humans
    113. Brenner MK. Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther. 2012 Dec; 19(12):818-21. PMID: 23059871.
      Citations: 8     Fields:    Translation:HumansCells
    114. Frederickson RM, Brenner MK. Assessing journal influence: impacted wisdom. Mol Ther. 2012 Aug; 20(8):1481. PMID: 22850716; PMCID: PMC3412488.
      Citations: 1     Fields:    
    115. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32. PMID: 22801446; PMCID: PMC3412490.
      Citations: 107     Fields:    Translation:HumansCells
    116. Lukianova-Hleb EY, Wagner DS, Brenner MK, Lapotko DO. Cell-specific transmembrane injection of molecular cargo with gold nanoparticle-generated transient plasmonic nanobubbles. Biomaterials. 2012 Jul; 33(21):5441-50. PMID: 22521612; PMCID: PMC3356440.
      Citations: 14     Fields:    Translation:HumansCells
    117. Brenner MK. Personalized medicine: words that mean just what you choose? Mol Ther. 2012 Feb; 20(2):241-2. PMID: 22297816; PMCID: PMC3277227.
      Citations: 2     Fields:    Translation:Humans
    118. Brenner MK. Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3. PMID: 22150365.
      Citations:    Fields:    Translation:HumansAnimalsCells
    119. Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, Leung KS, Kennedy-Nasser A, Brenner MK, Heslop HE, Liu H, Wu MF, Hanson IC, Krance RA. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83. PMID: 22078471; PMCID: PMC6173521.
      Citations: 26     Fields:    Translation:Humans
    120. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83. PMID: 22047558; PMCID: PMC3236370.
      Citations: 654     Fields:    Translation:HumansCellsCTClinical Trials
    121. Shaffer DR, Sheehan AM, Yi Z, Rodgers CC, Bollard CM, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61. PMID: 21994111; PMCID: PMC3258475.
      Citations: 1     Fields:    Translation:HumansCells
    122. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6. PMID: 21984804; PMCID: PMC3234664.
      Citations: 490     Fields:    Translation:HumansCellsCTClinical Trials
    123. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68. PMID: 21915103; PMCID: PMC3242656.
      Citations: 39     Fields:    Translation:HumansCells
    124. Capitini CM, Gottschalk S, Brenner M, Cooper LJ, Handgretinger R, Mackall CL. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60. PMID: 21854215.
      Citations: 2     Fields:    Translation:Humans
    125. Brenner MK. Stemming our irrational exuberance. Mol Ther. 2011 Aug; 19(8):1399-400. PMID: 21804613; PMCID: PMC3149166.
      Citations:    Fields:    Translation:HumansCells
    126. Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39. PMID: 21745159; PMCID: PMC3687103.
      Citations: 8     Fields:    Translation:HumansCells
    127. Brenner MK. Midlife moments. Mol Ther. 2011 May; 19(5):815-6. PMID: 21532604; PMCID: PMC3098645.
      Citations: 2     Fields:    
    128. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6. PMID: 21540550; PMCID: PMC3083795.
      Citations: 473     Fields:    Translation:HumansCells
    129. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62. PMID: 21278353; PMCID: PMC3069675.
      Citations: 42     Fields:    Translation:HumansCells
    130. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Heslop HE, Brenner MK, Krance RA. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51. PMID: 21108446.
      Citations: 4     Fields:    Translation:Humans
    131. Bonini C, Brenner MK, Heslop HE, Morgan RA. Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20. PMID: 21195304; PMCID: PMC3053011.
      Citations: 19     Fields:    Translation:HumansCells
    132. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90. PMID: 20948438; PMCID: PMC2964409.
      Citations: 86     Fields:    Translation:HumansCellsCTClinical Trials
    133. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9. PMID: 20429793; PMCID: PMC2914831.
      Citations: 34     Fields:    Translation:Cells
    134. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8. PMID: 20842059; PMCID: PMC2998197.
      Citations: 237     Fields:    Translation:HumansAnimalsCells
    135. Brenner MK. Clinical success of complex biological therapies: be careful what you wish for... Mol Ther. 2010 Oct; 18(10):1737-8. PMID: 20885429; PMCID: PMC2951574.
      Citations:    Fields:    Translation:Humans
    136. Turnis ME, Song XT, Bear A, Foster AE, Gottschalk S, Brenner MK, Chen SY, Rooney CM. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32. PMID: 20817880; PMCID: PMC3153346.
      Citations: 18     Fields:    Translation:AnimalsCells
    137. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, Simmons PJ, Sensebe L, Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010 Sep; 12(5):576-8. PMID: 20735162.
      Citations: 118     Fields:    Translation:HumansAnimalsCells
    138. Melenhorst JJ, Leen AM, Bollard CM, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE, Quigley MF. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2. PMID: 20709906; PMCID: PMC2996125.
      Citations: 76     Fields:    Translation:HumansCells
    139. Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15. PMID: 20506146; PMCID: PMC3290395.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    140. Brenner M. T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1. PMID: 20448573.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    141. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81. PMID: 20348004; PMCID: PMC2919628.
      Citations: 18     Fields:    Translation:Humans
    142. Brenner M. The eyes have it. Mol Ther. 2010 Mar; 18(3):451-2. PMID: 20195259; PMCID: PMC2839445.
      Citations: 4     Fields:    Translation:Humans
    143. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7. PMID: 20171074; PMCID: PMC3093371.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    144. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703. PMID: 20110422; PMCID: PMC2852368.
      Citations: 47     Fields:    Translation:HumansCells
    145. Okur FV, Brenner MK. Cellular immunotherapy of cancer. Methods Mol Biol. 2010; 651:319-45. PMID: 20686975.
      Citations: 5     Fields:    Translation:HumansCells
    146. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009 Nov 18; 8:106. PMID: 19922650; PMCID: PMC2784756.
      Citations: 3     Fields:    Translation:HumansCells
    147. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov; 20(11):1229-39. PMID: 19702437; PMCID: PMC2829458.
      Citations: 45     Fields:    Translation:HumansCells
    148. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35. PMID: 19880495; PMCID: PMC2817637.
      Citations: 331     Fields:    Translation:HumansCellsCTClinical Trials
    149. Vera JF, Brenner MK, Dotti G. Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther. 2009 Oct; 9(5):396-408. PMID: 19860654; PMCID: PMC2952647.
      Citations: 14     Fields:    Translation:HumansCells
    150. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91. PMID: 19759356; PMCID: PMC2786289.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    151. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Anichini A, Dotti G, Brenner MK, Dutour A. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60. PMID: 19737958; PMCID: PMC2745508.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    152. Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20. PMID: 19729196.
      Citations: 45     Fields:    Translation:HumansAnimalsCTClinical Trials
    153. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92. PMID: 19700662; PMCID: PMC2774556.
      Citations: 143     Fields:    Translation:HumansCellsCTClinical Trials
    154. Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25. PMID: 19584818; PMCID: PMC2835253.
      Citations: 37     Fields:    Translation:HumansCells
    155. Knippertz I, Hesse A, Schunder T, Brenner MK, Schuler G, Steinkasserer A, Nettelbeck DM, K?mpgen E. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun; 32(5):524-38. PMID: 19609245.
      Citations: 14     Fields:    Translation:HumansCells
    156. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67. PMID: 19443656; PMCID: PMC2738578.
      Citations: 98     Fields:    Translation:HumansCells
    157. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402. PMID: 19377047; PMCID: PMC2710932.
      Citations: 237     Fields:    Translation:HumansAnimalsCells
    158. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8. PMID: 19259067; PMCID: PMC2835146.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    159. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81. PMID: 20008253; PMCID: PMC2929387.
      Citations: 4     Fields:    Translation:HumansCells
    160. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70. PMID: 18978797; PMCID: PMC2749734.
      Citations: 579     Fields:    Translation:HumansCells
    161. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52. PMID: 18940679.
      Citations: 26     Fields:    Translation:HumansCells
    162. Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304. PMID: 18940685.
      Citations: 7     Fields:    Translation:Humans
    163. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008 Nov-Dec; 31(9):812-9. PMID: 18833006.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    164. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50. PMID: 18971421; PMCID: PMC2656271.
      Citations: 58     Fields:    Translation:HumansCellsCTClinical Trials
    165. Foster AE, Brenner MK, Dotti G. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):375-89. PMID: 18790444; PMCID: PMC2758265.
      Citations: 3     Fields:    Translation:HumansCells
    166. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74. PMID: 18600178; PMCID: PMC2643068.
      Citations: 11     Fields:    Translation:HumansCells
    167. Heslop HE, Brenner MK. The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1. PMID: 18725876.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    168. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5. PMID: 18463534; PMCID: PMC2745436.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    169. Kim H, Peng G, Hicks JM, Weiss HL, Van Meir EG, Brenner MK, Yotnda P. Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther. 2008 Mar; 16(3):599-606. PMID: 18227840.
      Citations: 25     Fields:    Translation:HumansCells
    170. Brenner MK. Developing T-cell therapies for cancer in an academic setting. Adv Exp Med Biol. 2008; 610:88-99. PMID: 18593017.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    171. Kennedy-Nasser AA, Brenner MK. T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007 Nov; 14(6):616-24. PMID: 17898565.
      Citations: 7     Fields:    Translation:HumansCells
    172. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54. PMID: 17942545; PMCID: PMC2224388.
      Citations: 71     Fields:    Translation:HumansCells
    173. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802. PMID: 17638856; PMCID: PMC2018664.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    174. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45. PMID: 17609424; PMCID: PMC2018666.
      Citations: 157     Fields:    Translation:HumansCellsCTClinical Trials
    175. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24. PMID: 17640595; PMCID: PMC2040267.
      Citations: 104     Fields:    Translation:HumansCells
    176. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30. PMID: 17507664; PMCID: PMC1988944.
      Citations: 114     Fields:    Translation:HumansAnimalsCells
    177. Tey SK, Brenner MK. The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76. PMID: 17299400.
      Citations: 6     Fields:    Translation:HumansCells
    178. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007 Feb-Mar; 30(2):227-33. PMID: 17471169.
      Citations: 20     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    179. Olmsted-Davis E, Gannon FH, Ozen M, Ittmann MM, Gugala Z, Hipp JA, Moran KM, Fouletier-Dilling CM, Schumara-Martin S, Lindsey RW, Heggeness MH, Brenner MK, Davis AR. Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol. 2007 Feb; 170(2):620-32. PMID: 17255330; PMCID: PMC1851874.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    180. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84. PMID: 17162209.
      Citations: 29     Fields:    Translation:HumansCells
    181. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6. PMID: 16998485.
      Citations: 254     Fields:    Translation:HumansCells
    182. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7. PMID: 16926291; PMCID: PMC1895462.
      Citations: 152     Fields:    Translation:HumansAnimalsCells
    183. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9. PMID: 16835376; PMCID: PMC1895521.
      Citations: 84     Fields:    Translation:HumansCells
    184. Boehnke A, Chapuy B, Glass B, Hemmerlein B, Schroers R, Brenner MK, Truemper L, Wulf GG. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94. PMID: 16818275.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    185. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808. PMID: 16741253; PMCID: PMC1895537.
      Citations: 81     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    186. Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60. PMID: 16699368.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    187. Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7. PMID: 16507214.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    188. Pscherer S, Altvater B, Pule M, Rooney CM, Brenner MK, Vormoor J, Rossig C, B?r A, J?rgens H. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31. PMID: 16365597.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    189. Biagi E, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK, Rousseau RF, Dutour A. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41. PMID: 16249392; PMCID: PMC1895421.
      Citations: 24     Fields:    Translation:HumansCells
    190. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23. PMID: 16203783.
      Citations: 26     Fields:    Translation:HumansCells
    191. Brenner MK, Rousseau RF. Vaccine therapies for pediatric malignancies. Cancer J. 2005 Jul-Aug; 11(4):331-9. PMID: 16197723.
      Citations: 7     Fields:    Translation:HumansCells
    192. Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK, Pul? MA. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41. PMID: 15979412.
      Citations: 223     Fields:    Translation:HumansCells
    193. Straathof KC, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM, Pul? MA. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54. PMID: 15728125; PMCID: PMC1895037.
      Citations: 297     Fields:    Translation:HumansAnimalsCells
    194. Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E, Vigouroux S, Brenner MK, Rooney CM. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005 Jun 15; 105(12):4677-84. PMID: 15713795; PMCID: PMC1895003.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    195. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33. PMID: 15611290; PMCID: PMC2211993.
      Citations: 131     Fields:    Translation:HumansCells
    196. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904. PMID: 15542583.
      Citations: 128     Fields:    Translation:HumansCellsCTClinical Trials
    197. Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood. 2005 Mar 15; 105(6):2436-42. PMID: 15536147.
      Citations: 21     Fields:    Translation:HumansCells
    198. Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC, Brenner MK, McMasters KM, Zhou HS. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther. 2004 Sep; 11(9):585-93. PMID: 15338010.
      Citations: 19     Fields:    Translation:HumansCells
    199. Leen AM, Sili U, Vanin EF, Jewell AM, Xie W, Vignali D, Piedra PA, Brenner MK, Rooney CM. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40. PMID: 15265797.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    200. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27. PMID: 15235393.
      Citations: 32     Fields:    Translation:HumansCells
    201. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004 Jul; 10(1):5-18. PMID: 15233937.
      Citations: 27     Fields:    Translation:HumansCells
    202. Brenner MK. Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract Res Clin Haematol. 2004 Jun; 17(2):359-74. PMID: 15302346.
      Citations: 2     Fields:    Translation:HumansCells
    203. Yotnda P, Savoldo B, Charlet-Berguerand N, Rooney C, Brenner M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80. PMID: 15161664.
      Citations: 14     Fields:    Translation:HumansCells
    204. Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood. 2004 Jul 01; 104(1):26-33. PMID: 15026316.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    205. Norwood K, Wang RY, Hirschmann-Jax C, Andreeff M, Brenner MK, Goodell MA, Wulf GG. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res. 2004 Mar; 28(3):295-9. PMID: 14687625.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    206. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008. PMID: 14985264.
      Citations: 26     Fields:    Translation:HumansCells
    207. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70. PMID: 14769850; PMCID: PMC2211826.
      Citations: 59     Fields:    Translation:HumansCells
    208. Wagner HJ, Bollard CM, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM, Vigouroux S. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91. PMID: 14685154.
      Citations: 31     Fields:    Translation:HumansCells
    209. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81. PMID: 14751931.
      Citations: 46     Fields:    Translation:HumansCells
    210. Olmsted-Davis EA, Gugala Z, Camargo F, Gannon FH, Jackson K, Kienstra KA, Shine HD, Lindsey RW, Hirschi KK, Goodell MA, Brenner MK, Davis AR. Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):15877-82. PMID: 14673088; PMCID: PMC307661.
      Citations: 49     Fields:    Translation:AnimalsCells
    211. Leen AM, Sili U, Savoldo B, Jewell AM, Piedra PA, Brenner MK, Rooney CM. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9. PMID: 14525768.
      Citations: 37     Fields:    Translation:HumansCells
    212. Yvon E, Wagner HJ, Biagi E, Dotti G, Sili U, Lira C, Rooney CM, Brenner MK, Vigouroux S. Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol. 2003 Oct; 77(20):10872-80. PMID: 14512537; PMCID: PMC224961.
      Citations: 34     Fields:    Translation:HumansCells
    213. Takahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, Barry MA. Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7. PMID: 14500347.
      Citations: 8     Fields:    Translation:HumansCells
    214. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, Cavagnaro J, High K, Glorioso J, American Society of Gene Therapy (ASGT), Rivi?re I. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003 Aug; 8(2):180-7. PMID: 12907140.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    215. Yvon ES, Vigouroux S, Rousseau RF, Biagi E, Amrolia P, Dotti G, Wagner HJ, Brenner MK. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood. 2003 Nov 15; 102(10):3815-21. PMID: 12842995.
      Citations: 47     Fields:    Translation:HumansCells
    216. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54. PMID: 12788648.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    217. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9. PMID: 12763937.
      Citations: 39     Fields:    Translation:HumansCells
    218. Brenner MK, Wulf GG, Rill DR, Luo KL, Goodell MA, Mei Z, Kuehnle I, Brown MP, Pule M, Heslop HE, Krance RA. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8. PMID: 12799286.
      Citations: 8     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    219. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56. PMID: 12806278.
      Citations: 21     Fields:    Translation:HumansCells
    220. Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK, Rousseau RF. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59. PMID: 12718765.
      Citations: 7     Fields:    Translation:HumansCells
    221. Wulf GG, Luo KL, Jackson KA, Brenner MK, Goodell MA. Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica. 2003 Apr; 88(4):368-78. PMID: 12681963.
      Citations: 39     Fields:    Translation:AnimalsCells
    222. Krance RA, Kuehnle I, Rill DR, Mei Z, Pinetta C, Evans W, Brown MP, Heslop HE, Brenner MK, Pul? M. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81. PMID: 12720220.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    223. Biagi E, Bollard C, Brenner M, Rousseau R. [Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer. 2003 Mar; 90(3):227-38. PMID: 12801825.
      Citations:    Fields:    Translation:HumansCells
    224. Brenner MK, R?ssig C. Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003; 110(2-3):154-9. PMID: 14583676.
      Citations: 6     Fields:    Translation:HumansCells
    225. Biagi E, Bollard C, Rousseau R, Brenner M. Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives. J Biomed Biotechnol. 2003; 2003(1):13-24. PMID: 12686719; PMCID: PMC179759.
      Citations:    Fields:    
    226. Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, Wang RF. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9. PMID: 12499257.
      Citations: 23     Fields:    Translation:HumansCells
    227. Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D, Rousseau RF. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26. PMID: 12406881.
      Citations: 38     Fields:    Translation:HumansCellsCTClinical Trials
    228. Brenner M. Response to "systemic adenovirus delivery". Mol Ther. 2002 Aug; 6(2):138. PMID: 12161176.
      Citations:    Fields:    Translation:HumansCells
    229. Brenner M. Evidence-based regulation--a personal view. Mol Ther. 2002 Aug; 6(2):137. PMID: 12161175.
      Citations:    Fields:    Translation:Humans
    230. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16. PMID: 11877273.
      Citations: 81     Fields:    Translation:HumansCells
    231. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41. PMID: 11863412.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    232. Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner MK, Nuchtern JG. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 2002 Feb 15; 62(4):1123-8. PMID: 11861392.
      Citations: 34     Fields:    Translation:HumansCells
    233. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18. PMID: 11777989.
      Citations: 27     Fields:    Translation:HumansCells
    234. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33. PMID: 11785836.
      Citations: 18     Fields:    Translation:HumansCells
    235. Brenner M, Rossig C, Sili U, Young JW, Goulmy E. Transfusion Medicine: New Clinical Applications of Cellular Immunotherapy. Hematology Am Soc Hematol Educ Program. 2000; 356-375. PMID: 11701551.
      Citations: 1     Fields:    
    BRENNER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (657)
    Explore
    _
    Co-Authors (107)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _